<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in first complete remission in transplant-eligible patients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in first complete remission in transplant-eligible patients</h1>
<div class="graphic"><div class="figure"><div class="ttl">Management of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) in first complete remission in transplant-eligible patients</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm should be used in conjunction with related UpToDate content regarding transplant eligibility, detection of MRD, and related material.</div><div class="graphic_footnotes">Ph+ ALL: Philadelphia chromosome positive acute lymphoblastic leukemia; CR: hematologic complete remission; MRD: measurable residual disease based on quantitative reverse transcriptase polymerase chain reaction; HCT: hematopoietic cell transplantation; TKI: BCR-ABL1 tyrosine kinase inhibitor; MD-MTX: high-dose methotrexate.<br/>* MRD detected in bone marrow: &lt;MR4.5 (<em>BCR-ABL1</em> &gt;10<sup innerhtml="">–4.5</sup>).<br/>¶ Change to an alternate TKI must consider the TKI toxicity profile and comorbid conditions.<br/>Δ Some experts omit HCT for patients with no detectable MRD and proceed directly to maintenance therapy.</div><div id="graphicVersion">Graphic 130441 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
